ReNeuron Group plc Exercise of Share Options and TVR (0906W)
12 April 2019 - 11:36PM
UK Regulatory
TIDMRENE
RNS Number : 0906W
ReNeuron Group plc
12 April 2019
12 April 2019 AIM: RENE
ReNeuron Group plc
Exercise of Share Options and Director's Dealings
Total Voting Rights
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics,
announces that it has received notices to exercise options from
certain employees and a PDMR of the Company to subscribe for a
total of 12,478 new ordinary shares of 1 pence in the Company. The
exercise price of the options is GBP1.00 per share.
On 12 April 2019, Michael Hunt, Chief Financial Officer,
exercised options over 3,478 ordinary shares of 1p each in the
Company at an exercise price of GBP1.00 per share. In order to
achieve a cashless exercise and pay the relevant taxes, on 12 April
2019 Mr Hunt sold 988 shares at a share price of GBP2.47 and
therefore retains 2,490 shares.
As a result of the exercise and share transaction, Mr Hunt's
interest in ordinary shares has increased to 30,036 ordinary
shares, representing approximately 0.095% of the Company's issued
share capital.
Total voting rights
Following the issue of 12,478 ordinary shares pursuant to the
exercise of options described above and exercised through its
existing blocklisting arrangements, the Company has 31,658,664
ordinary shares in issue, all with voting rights. The Company holds
no ordinary shares in treasury. The above figure of 31,658,664 may
be used by shareholders as the denominator for the calculation by
which they will determine if they are required to notify their
interest in, or a change in their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa. ReNeuron is also
advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation and provide
further detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Michael Hunt
---------------------------- ----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Financial Officer
---------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- ----------------------------------
b) LEI N/A
---------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares 0.01p
the financial instrument,
type of instrument RENE - GB00B0DZML60
Identification
code
---------------------------- ----------------------------------
b) Nature of the transaction Exercise of options over ordinary
shares
---------------------------- ----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP1.00 3,478
----------
---------------------------- ----------------------------------
d) Aggregated information N/A
---------------------------- ----------------------------------
e) Date of the transaction 12 April 2019
---------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
---------------------------- ----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Michael Hunt
---------------------------- ----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Financial Officer
---------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- ----------------------------------
b) LEI N/A
---------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares 0.01p
the financial instrument,
type of instrument RENE - GB00B0DZML60
Identification
code
---------------------------- ----------------------------------
b) Nature of the transaction Sale of ordinary shares
---------------------------- ----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP2.47 988
----------
---------------------------- ----------------------------------
d) Aggregated information N/A
---------------------------- ----------------------------------
e) Date of the transaction 12 April 2019
---------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
---------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUUOORKSASAAR
(END) Dow Jones Newswires
April 12, 2019 09:36 ET (13:36 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024